Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 4, 2006, Pages 300-304

  Härtter, Sebastian ^b   Korhonen, Tuomas ^a   Lundgren, Stefan ^c   Rane, Anders ^c   Tolonen, Ari ^d   Turpeinen, Miia ^e   Laine, Kari ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Novamass Analytical Ltd   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; COFI TABS; CYTOCHROME P450 1A2; CYTOCHROME P450 1A2 1A; CYTOCHROME P450 1A2 1F; MELATONIN; UNCLASSIFIED DRUG;

ADULT; ALLELISM; ARTICLE; CLINICAL TRIAL; COFFEE; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; ENZYME MECHANISM; ENZYME REGULATION; FEMALE; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INHIBITION KINETICS; MALE; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CAFFEINE; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MELATONIN; POLYMORPHISM, GENETIC;

EID: 33750049024     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_491.x     Document Type: Article

References (40)

1. Aitchison, K. J., F. J. Gonzalez, L. C. Quattrochi, A. Sapone, J. H. Zhao, H. Zaher, G. Elizondo, C. Bryant, J. Munro, D. A. Collier, A. I. Makoffa & R. W. Kerwin: Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics 2000, 10, 695-704.
2. Bock, K. W., D. Schrenk, A. Forster, E. U. Griese, K. Mörike, D. Brockmeier & M. Eichelbaum: The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994, 4, 209-218.
3. Brøsen, K., E. Skjelbo, B. B. Rasmussen, H. E. Poulsen & S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 1993, 45, 1211-1214.
4. Butler, M. A., M. Iwasaki, F. P. Guengerich & F. F. Kadlubar: Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U S A 1989, 86, 7696-7700.
5. Campbell, M. E., D. M. Grant, T. Inaba & W. Kalow: Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug. Metab. Dispos. 1987, 15, 237-249.
6. Chung, I. & E. Bresnick: Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins. Mol. Pharmacol. 1995, 47, 677-685.
7. Demisch, K., L. Demisch, T. Nickelsen & R. Rieth: The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J. Neural. Transm. 1987, 68, 257-270.
8. Dorne, J. L., K. Walton & A. G. Renwick: Uncertainty factors for chemical risk assessment. human variability in the pharmaco kinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 2001, 39, 681-696.
9. Eaton, D. L., E. P. Gallagher, T. K. Bammler & K. L. Kunze: Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 1995, 5, 259-274.
10. Facciolá, G., M. Hidestrand, C. von Bahr & G. Tybring: Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol. 2001, 56, 881-888.
11. Fuhr, U., E. M. Anders, G. Mahr, F. Sorgel & A. H. Staib: Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob. Agents Chemother. 1992, 36, 942-948.
12. Fuhr, U., K. L. Rost, R. Engelhardt, M. Sachs, D. Liermann, C. Belloc, P. Beaune, S. Janezic, D. Grant, U. A. Meyer & A. H. Staib: Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996, 6, 159-176.
13. Grözinger, M., S. Härtter, D.-M. Rose, X. Wang, J. Röschke, C. Hiemke: Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. Arch. Gen. Psychiatry 2000a, 57, 812-813.
14. Han, X. M., D. S. Ou-Yang, P. X. Lu, C. H. Jiang, Y. Shu, X. P. Chen, Z. R. Tan & H. H. Zhou: Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001, 11, 429-435.
15. Härtter, S., M. Grozinger, H. Weigmann, J. Roschke & C. Hiemke: Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin. Pharmacol. Therap. 2000, 67, 1-6.
16. Härtter, S., A. Nordmark, D.-M. Rose, L. Bertilsson, G. Tybring & K. Laine: Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Brit. J. Clin. Pharmacol. 2003, 56, 679-682.
17. Härtter, S., C. Ursing, S. Morita, G. Tybring, C. von Bahr, M. Christensen, S. Röjdmark & L. Bertilsson: Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin. Pharmacol. Therap. 2001a, 70, 10-16.
18. Härtter, S., X. Wang, H. Weigmann, T. Friedberg, M. Arand, F. Oesch & C. Hiemke: Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J. Clin. Psychopharmacol. 2001b, 21, 167-174.
19. Kall, M. A. & J. Clausen: Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man. Hum. Exp. Toxicol. 1995, 14, 801-807.
20. Kalow, W. & B. K. Tang: Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Therap. 1991, 50, 508-519.
21. Kootstra-Ros, J. E., W. Smallegoor & J. van der Weide: The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann. Clin. Biochem. 2005, 42, 216-219.
22. Laine, K., S. Palovaara, P. Tapanainen & P. Manninen: Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin. Pharmacol. Therap. 1999, 66, 602-608.
23. Lampe, J. W., I. B. King, S. Li, M. T. Grate, K. V. Barale, C. Chen, Z. Feng & J. D. Potter: Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000, 21, 1157-1162.
24. Landi, M. T., R. Sinha, N. P. Lang & F. F. Kadlubar: Human cytochrome P4501A2. In: Metabolic polymorphisms and susceptibility to cancer. Ed.: W. Ryder. IARC Scientific Publications No 148, Lyon, France, 1999, 173-195.
25. Le Marchand, L., A. A. Franke, L. Custer, L. R. Wilkens & R. V. Cooney: Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics 1997, 7, 11-19.
26. Ma, X., J. R. Idle, K. W. Krausz & F. J. Gonzalez. Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos. 2005, 33, 489-494.
27. Nakajima, M., T. Yokoi, M. Mizutani, M. Kinoshita, M. Funayama & T. Kamataki: Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (Tokyo) 1999, 125, 803-808.
28. Nordmark, A., S. Lundgren, B. Ask, F. Granath & A. Rane: The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Brit. J. Clin. Pharmacol. 2002, 54, 504-510.
29. Rost, K. L. & I. Roots: Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin. Pharmacol. Therap. 1994, 55, 402-411.
30. Rostami-Hodjegan, A., S. Nurminen, P. R. Jackson & G. T. Tucker: Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996, 6, 121-149.
31. Sachse, C., J. Bröckmoller, S. Bauer & I. Roots.: Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Brit. J. Clin. Pharmacol. 1999, 47, 445-449.
32. Sato, J., H. Nakata, E. Owada, T. Kikuta, M. Umetsu & K. Ito: Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur. J. Clin. Pharmacol. 1993, 44, 295-298.
33. Schrenk, D., D. Brockmeier, K. Mörike, K. W. Bock & M. Eichelbaum: A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol. 1998, 53, 361-367.
34. Skene, D. J., E. Papagiannidou, E. Hashemi, J. Snelling, D. F. Lewis, M. Fernandez & C. Ioannides: Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J. Pineal. Res. 2001, 31, 333-342.
35. Streetman, D. S., J. S. Bertino Jr. & A. N. Nafziger: Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000, 10, 187-216.
36. Tantcheva-Poór, I., M. Zaigler, S. Rietbrock & U. Fuhr: Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999, 9, 131-144.
37. Ursing, C., C. von Bahr, K. Brismar & S. Röjdmark: Influence of cigarette smoking on melatonin levels in man. Eur. J. Clin. Pharmacol. 2005, 61, 197-201.
38. Vainer, J. L. & G. Chouinard: Interaction between caffeine and clozapine. J. Clin. Psychopharmacol. 1994, 14, 284-285.
39. von Bahr, C., C. Ursing, N. Yasui, G. Tybring, L. Bertilsson & S. Röjdmark: Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur. J. Clin. Pharmacol. 2000, 56, 123-127.
40. Young, I. M., R. M. Leone, P. Francis, P. Stovell & R. E. Silman: Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J. Clin. Endocrinol. Metab. 1985, 60, 114-119.